<DOC>
	<DOCNO>NCT00999843</DOCNO>
	<brief_summary>Patients liver cancer receive interventional therapy plus radiotherapy . Maintenance Sorafenib take completion radiotherapy . Hypothesis current study Sorafenib maintenance therapy safe superior radiotherapy combine interventional therapy term survival comparison historical data .</brief_summary>
	<brief_title>Safety Study Sorafenib Following Combined Therapy Radiation TACE Liver Cancer</brief_title>
	<detailed_description>Patients solitary lesion ( big 5 cm diameter ) histologically cytologically confirm HCC receive TACE ( 1-3 cycle ) plus 3DCRT/IMRT 4-6 week later . Maintenance Sorafenib administer patient non-progression disease 4 6 week completion radiotherapy . The dose 400 mg , p.o. , twice day . Sorafenib continuously give 12 month unless intolerable toxicity and/or tumor progression . Hypothesis current study Sorafenib maintenance therapy combine therapy 3DCRT/IMRT TACE safe superior radiotherapy combine TACE alone term time progression ( TTP ) , progression-free survival ( PFS ) overall survival ( OS ) comparison historical data .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Age equal old 18 year 75 year life expectancy least 12 week ; 2 . Karnofsky performance status ( KPS ) â‰¥70 ; 3 . Histologically cytologically confirm HCC ; 4 . BCLC stage B , solitary lesion ( big 5 cm diameter ) tumor burden le 50 % total liver volume ; 5 . Liver function ChildPugh A ; 6 . Technically unresectable , medically inoperable , surgery decline patient ; 7 . Normal renal function adequate bone marrow reservation ; 8 . Signed informed consent must obtain prior study specific procedure . 1 . Presence intrahepatic and/or extrahepatic metastasis 2 . Previous receive systemic therapy liver cancer ; 3 . History radiotherapy liver ; 4 . Indistinct tumor boundary CT/MRI image ; 5 . Previous concurrent malignancy , exception adequately treat basal cell carcinoma skin situ carcinoma cervix superficial bladder tumor [ Ta , Tis T1 ] ; 6 . History cardiac disease : congestive heart failure &gt; NYHA class 2 , active CAD , cardiac arrythmias require antiarrhythmic therapy uncontrolled hypertension within last 12 month ; 7 . Concurrent uncontrolled medical condition ; 8 . Pregnancy breast feeding ; 9 . Investigational drug therapy outside trial within 4 week study entry ; 10 . Psychiatric medical unstable condition compromise patient 's ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Three-dimensional conformal radiation therapy</keyword>
	<keyword>Intensity-modulated radiation therapy</keyword>
	<keyword>Transcatheter arterial chemoembolization</keyword>
</DOC>